Aldebaran Therapeutics focuses on developing innovative therapies for neurological and psychiatric disorders, leveraging its proprietary technologies to create targeted treatments. The company employs a unique approach that combines advanced drug delivery systems with a deep understanding of the underlying biology of these conditions. This enables Aldebaran to design therapies that can effectively reach their intended targets in the brain, potentially improving efficacy and reducing side effects compared to traditional treatments.

The company's pipeline includes a range of product candidates that utilize its specialized technologies, which are aimed at addressing unmet medical needs in the field of neuroscience. Aldebaran's commitment to scientific rigor and innovation is evident in its research and development efforts, which are grounded in a thorough understanding of the mechanisms of action of its therapeutic candidates. By focusing on precision medicine, Aldebaran Therapeutics aims to provide more effective and personalized treatment options for patients suffering from complex neurological disorders.

United States

Aldebaran Therapeutics leverages human genetics and best-in-class antisense oligonucleotide (ASO) technology to deliver life-changing, precision ocular ASO medicines. Our focus on differentiated ASO technology, powered by Alloy Therapeutics' Genetic Medicines platform and novel AntiClastic™ ASO format, paves the way for a unique and rapid path to meaningful ocular solutions for patients.

Aldebaran Therapeutics

Company Details